Free Widgets | Feedback 
Live Share Markets - Appuonline.com


Updated:29 Jun 2017 03:31:00 PM(IST)

Investor Tool

My Stockwatch 

RELIANCE 1392.70 [ -0.41% ]TCS 2333.25 [ -0.71% ]

Sensex30857.52
23.20 0.08%

Nifty9504.10
12.85 0.14%

Midcap14552.49
49.80 0.34%

Smallcap15310.21
148.89 0.98%


Bse Corporate Announcements Back
Cipla gets tentative approval for the Rizatriptan Benzonate
Cipla gets tentative approval for the Rizatriptan Benzonate Teva Pharmaceuticals, Mylan Pharmaceuticals and Sandoz already received tentative approvals Cipla gets tentative approval for the Abbreviated New Drug Application (ANDA) from US Food and Drug Application (FDA) for the Rizatriptan Benzonate tablets in the strengths of 5 mg and 10 mg tablets. It was originally developed and marketed by the Merck under the brand name drug Maxalt. It is indicated in the treatment of the migrane. According to the Merck 2009 annual report, it has annual sales of USD 574.5 million. The patent is set to expire in 2012. Further, Teva Pharmaceuticals, Mylan Pharmaceuticals, Sandoz already received tentative approvals.

Market on Mobile
























Site Map  •  Mobile  •  Companies  •  Learning Centre  •  Insurance •  About  •  Contact us  •  Disclaimer
© appuonline.com